BGI Reports the Availability of RT-PCR SARS-CoV-2 Test for Clinical Use in the US

BGI Reports the Availability of RT-PCR SARS-CoV-2 Test for Clinical Use in the US

Shots:

  • BGI’s Real-Time Fluorescent RT-PCR test is now commercially available in the US for detecting SARS-CoV-2. Following the FDA’s guidance, BGI’s detection kit is eligible to be used instantly to accelerate clinical testing for COVID-19
  • BGI has applied to the US FDA for EUA for its detection kit and has received NMPA’s approval on Jan 26, 2020, followed by CE-IVD marking on Mar 2, 2020.
  • BCI has scaled up manufacturing with a daily capacity of up to 300,000 reactions per day and is distributing its SARS-CoV-2 detection kits to 50+ countries and regions around the globe

Click here to­ read full press release/ article | Ref: BGI | Image: BGI